Opioid Blister Packs Need Study Before Mandate, Groups Urge
Executive Summary
AAM, Upsher-Smith, APhA, and Cigna tell US FDA that packaging requirement will increase manufacturing and drug costs, create reimbursement hurdles and reduce access to medicines. Daiichi-Sankyo supports agency's proposal.
You may also be interested in...
US FDA Says Opioid Database Firm With Purdue Pharma Connections Reported No Conflicts
Amid criticism of its contract to evaluate opioid data from the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) survey programs, the FDA says federal databases lack the necessary information on opioid misuse.
US FDA Looking For Senior Leader In New Drugs Office To Oversee Substance Use Disorder Issues
The deputy Office of New Drugs director will have decision-making authority and help shape policy for substance use efforts.
New Opioid Labeling Further Constrains Use, Urges Prescribing Only By Docs ‘Knowledgeable’ About Risks
US FDA’s mandated labeling changes come after the agency required manufacturers to provide mail-back envelopes for opioid disposal.